Spinocerebellar ataxia type 1 (SCA1) is one of nine inherited, typically adult onset, polyglutamine neurodegenerative diseases. To examine whether development impacts SCA1, we used a conditional transgenic mouse model of SCA1 to delay the postnatal expression of mutant ATXN1 until after completion of cerebellar development. Delayed postnatal expression of mutant ATXN1 led to a substantial reduction in severity of disease in adults in comparison with early postnatal gene expression. This was linked to a destabilization of RORa, a transcription factor critical for cerebellar development. In SCA1 mice, there was a depletion of RORa and a reduction in expression of genes controlled by RORa. Partial loss of RORa enhanced mutant ATXN1 pathogenicity. Additionally, evidence points to the existence of a complex containing ATXN1, RORa, and the RORa coactivator Tip60. These studies indicate RORa and Tip60 have a role in SCA1 and suggest a mechanism by which compromising cerebellar development contributes to severity of neurodegeneration in an adult.
SUMMARY
Spinocerebellar ataxia type 1 (SCA1) is one of nine inherited, typically adult onset, polyglutamine neurodegenerative diseases. To examine whether development impacts SCA1, we used a conditional transgenic mouse model of SCA1 to delay the postnatal expression of mutant ATXN1 until after completion of cerebellar development. Delayed postnatal expression of mutant ATXN1 led to a substantial reduction in severity of disease in adults in comparison with early postnatal gene expression. This was linked to a destabilization of RORa, a transcription factor critical for cerebellar development. In SCA1 mice, there was a depletion of RORa and a reduction in expression of genes controlled by RORa. Partial loss of RORa enhanced mutant ATXN1 pathogenicity. Additionally, evidence points to the existence of a complex containing ATXN1, RORa, and the RORa coactivator Tip60. These studies indicate RORa and Tip60 have a role in SCA1 and suggest a mechanism by which compromising cerebellar development contributes to severity of neurodegeneration in an adult.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is one of nine inherited diseases known as polyglutamine neurodegenerative disorders Taylor et al., 2002) . The mutational mechanism of these diseases is the expansion of a CAG trinucleotide repeat that encodes a polyglutamine stretch within each respective diseasecausing protein. Typical of the autosomal dominant ataxias, SCA1 is characterized by a progressive loss of motor coordination, speech impairment, and problems with swallowing. Although the SCA1 encoded protein ATAXIN 1 (ATXN1) is widely expressed Banfi et al., 1996) , in SCA1, mutant ATXN1 causes neurodegeneration predominantly of cerebellar Purkinje cells and neurons in the brain stem and spinal cord (Clark and Orr, 2000) .
Studies utilizing animal models have provided considerable insight into mechanisms of pathogenesis. Sca1 null mice fail to develop ataxia and Purkinje cell pathology (Matilla et al., 1998) . In contrast, mice that either overexpress mutant ATXN1 or mice that have a targeted insertion of 154 repeats into the endogenous Sca1 locus develop ataxia and Purkinje cell pathology similar to that seen in SCA1 patients (Burright et al., 1995; Watase et al., 2002) . Transgenic mouse studies demonstrated that while mutant ATXN1 must enter the nucleus of Purkinje cells to cause disease, formation of the inclusions per se was not required for the initiation of disease (Klement et al., 1998) . Further, misfolding and impaired degradation of mutant ATXN1 likely contributes to pathogenesis (Cummings et al., 1998 (Cummings et al., , 1999 (Cummings et al., , 2001 ). Phosphorylation of Ser776 in mutant ATXN1 is important for pathogenesis (Emamian et al., 2003) , likely because this modification of ATXN1 is involved in its stabilization by regulating its interaction with the cellular protein 14-3-3 (Chen et al., 2003) . Specific genes whose expression is downregulated prior to the onset of pathology were identified (Lin et al., 2000; Serra et al., 2004) . Several nuclear proteins that interact with ATXN1 have been identified as possible mediators of SCA1 pathogenesis, including PQBP, SMRT, BOAT, and Gfi-1 (Okazawa et al., 2002; Tsai et al., 2004; Tsuda et al., 2005 ). Yet, even with these advances, the molecular mechanism by which a mutant ATXN1-induced alteration in gene expression results in the degeneration of only certain neurons, such as cerebellar Purkinje cells, remains unknown. Here we show that developmental timing of mutant SCA1 expression has a substantial impact upon disease and suggest a mechanism by which mutant ATXN1 compromises cerebellar development and, thus, contributes to severity of neurodegeneration in adult mice.
RESULTS

Expression of Mutant ATXN1 during Cerebellar Development Enhances Disease
In the original series of SCA1[82Q] transgenic mice, one line, designated B04, stood out as having a relatively low level of SCA1 expression yet developed a severe ataxia ( Figure S1 ; Burright et al., 1995) . An interesting feature of SCA1 expression in line B04 is that it began on postnatal day 2. In the other SCA1[82Q] lines, exemplified by line B05, transgene expression begins during postnatal week 2 (days P10-P14).
Since the first 3 postnatal weeks are a critical period for Purkinje cell and cerebellar cortex development in the mouse (Goldowitz and Hamre, 1998) , we hypothesized that the increased susceptibility to mutant ATXN1 in SCA1[82Q] B04 mice might be due to expression of the SCA1[82Q] transgene for a greater portion of the critical period of postnatal development. The availability of a doxycycline-regulated conditional transgenic mouse model of SCA1 (Zu et al., 2004 ) allowed us to test this idea.
The strategy utilized was to compare disease in two groups of conditional SCA1[82Q] transgenic mice. Both groups were exposed to mutant ATXN1 expression for a total of 12 weeks. In one group, the 12 week gene-on group, SCA1 transgene expression was allowed to begin during postnatal week 2. In the second group SCA1 transgene expression was delayed for 14 weeks, until well after the cerebellum had matured, and then turned on for 12 weeks. The time course of SCA1 transgene expression in each group of mice was confirmed by northern blot analysis ( Figure 1A ). In the 12 week gene-on mice, SCA1 mRNA was first detectable at day P3, reaching the maximum level of expression by day P10. In the 14 week gene-off/12 week gene-on mice, expression of the SCA1 transgene was suppressed for 14 weeks. By 2 days after removing doxycycline, the SCA1 transgene reached a maximum level of expression similar to the maximum level of expression seen with the 12 week-gene-on mice.
Disease severity in the 12 week gene-on mice and the 14 week gene-off/12 week gene-on mice was assessed using both neurological and pathological criteria. By home cage behavior, the 12 week gene-on SCA1 [82Q] mice had a moderate level of ataxia as reported previously (Zu et al., 2004) . In contrast, the 14 week gene-off/12 week gene-on SCA1[82Q] mice showed no signs of ataxia. Consistent with the home cage behavior observations, the 14 week gene-off/12 week gene-on mice performed markedly better on the accelerating Rotarod than did the 12 week gene-on mice ( Figure 1B ). Figure 1D ). This milder Purkinje cell pathology continued to be observed when the 14 week gene-off/gene-on SCA1[82Q] mice were allowed to age further with the gene-on period extended to 24 weeks ( Figure 1E ). In 14 week gene-off/24 week gene-on mice, the thickness of the molecular layer remained greater than the molecular layer in mice where SCA1[82Q] was expressed for 24 weeks straight.
To further focus on the critical period where the lack of mutant ATXN1 expression seems to protect Purkinje cells from the effects of subsequent expression of mutant ATXN1, we generated mice where SCA1[82Q] was expressed for 12 weeks following off periods of either the first 2 or 3 postnatal weeks. At both the primary fissure and a posterior fissure, gene-off periods for the first 2 and 3 postnatal weeks also had a protective effect on the thickness of the molecular layer ( Figure 1D ).
These data indicate that the timing of mutant ATXN1 expressed during the first postnatal weeks, i.e., during a critical period of cerebellar development and maturation, modifies subsequent disease severity in the adult. One potential explanation for this developmental effect on SCA1 severity is that ATXN1 interacts with a pathway involved in Purkinje cell development.
RORa-Regulated Genes Are Downregulated in the Cerebella of SCA1[82Q] Mice Previously, using a subtractive cDNA approach (Lin et al., 2000) as well as a microarray-based gene profiling strategy (Serra et al., 2004) , we identified four genes whose expression is regulated by RORa (Gold et al., 2003) . Subsequently, we analyzed the SCA1 gene-profile data set with a set of analytical programs specifically designed for microarray data. This analysis yielded an expanded SCA1-selected set of 53 genes, 13 of which increased in expression with disease and 40 of which decreased in expression with disease (Table S1 ).
When the set of 40 genes with a decreased expression in 5 week-old SCA1 [82Q] mice was compared to the entire set of RORa-mediated genes generated by Gold et al. (2003) , considerable overlap was found (Table 1) . Among the RORa-responsive genes in the SCA1 gene set were all four of the genes to which RORa has been found to bind directly to their promoters in vivo (Gold et al., 2003) . These data indicated that RORa-mediated genes are, as a group, downregulated at an early stage of disease in Purkinje cells of SCA1[82Q] mice.
RORa Is Decreased in Purkinje Cells of SCA1[82Q] Transgenic Mice
To examine whether a decrease in RORa might be the cause of the decrease in RORa-mediated gene expression seen in cerebella from the SCA1 mice, we used immunofluorescence to assess RORa expression. Figure 2A shows the level of RORa immunostaining in the nuclei of wild-type mouse Purkinje cells as well as the level of staining in the nuclei of specific interneurons in the molecular layer. In contrast, the levels of RORa staining in Purkinje cell nuclei in a 12 week-old SCA1[82Q] heterozygous mouse ( Figure 2B ) was noticeably less than RORa staining in the nuclei of wild-type Purkinje cells. Sca1À/À mice ( Figure 2C ) and mice overexpressing a wild-type allele of SCA1 ( Figure 2D ) had levels of RORa in their Purkinje cells that appeared similar to those seen in wild-type mice. To quantitatively assess the levels of RORa, we determined the mean pixel density of RORa-positive Purkinje cell and interneuron nuclei ( Figure 2E ). This analysis showed that there were significant decreases in the levels of RORa in the Purkinje cell nuclei of SCA1 [30Q] and SCA1[82Q] compared to wild-type mice.
To obtain a more quantitative assessment of RORa levels, we performed western blot analyses. As a specificity control, the amount of RORa in a cerebellar lysate prepared from a staggerer (sg/sg) mouse, a null mutation at Rora (Hamilton et al., 1996) , was determined and found to be negligible compared to the level of RORa in cerebellar lysate from a wild-type mouse ( Figure Figure 3A , lane 2), that does not cause disease due to a mutation in the nuclear localization sequence preventing the protein from entering the nucleus (Klement et al., 1998) . Moreover, mice overexpressing wild-type ATXN1, ATXN1[30Q], also had levels of RORa similar to nontransgenic wild-type mice ( Figure 3A , lane 7). Thus, decreased levels of RORa were found only in cerebellar extracts from mice expressing a mutant form of ATXN1 that caused ataxia.
To gain insight into the molecular basis for the loss of RORa from Purkinje cell nuclei in the presence of mutant ATXN1, northern blots were performed. As shown in Figure 3D , the amount of RORa mRNA in a SCA1 [82Q] cerebellum was decreased compared to wild-type, SCA1 [30Q] , or Sca1À/À mice. Thus, in the presence of mutant ATXN1, both RORa protein and mRNA levels were reduced. The conditional SCA1[82Q] mice were used to assess the relative contributions of RNA-based and protein-based mechanisms to the mutant ATXN1-induced decrease in RORa. The cerebellar levels of RORa protein and mRNA in 12 week gene-on mice were compared with those from 12 week gene-on/2 day gene-off mice. The results ( Figure 3E ) show that after turning the SCA1[82Q] gene off for 2 days the RORa protein was restored in absence of a restoration of the RORa-mRNA level. This result is consistent with mutant ATXN1 affecting RORa protein levels independent of its effect on RORamRNA levels.
Partial Loss of RORa Enhances the Pathogenicity of ATXN1[82Q] in Transgenic Mice
To evaluate the role of RORa in SCA1 pathogenesis in vivo using a genetic approach, we assessed the effect of a loss-of-function allele of Rora in Purkinje cells by placing 
** **Genes to which RORa binds to the promoter (Gold et al., 2003 Figure S2 ).
To examine whether this reflected a biochemical interaction between endogenous ATXN1 and RORa, we performed coimmunoprecipitation studies on cerebellar lysates prepared from normal and Sca1À/À mice. An immunoprecipitation using an antibody against RORa coimmunoprecipitated ATXN1 from a lysate prepared from a normal mouse cerebellum. Conversely, RORa coimmunoprecipitated with the anti-ATXN1 antibody 11750 ( Figure 5A ). Control immunoprecipitations using lysates prepared from the cerebella of Sca1À/À mice failed to bring down ATXN1 with the anti-RORa antibody or RORa with the anti-ATXN1 antibody. GST-ATXN1 pulldowns of in vitro transcribed/translated RORa were used to assess whether ATXN1 and RORa might interact directly. As show in Figure 5B , the results of this analysis failed to demonstrate an interaction. None of the following were able to able to pull down RORa above background levels observed with GST alone: GST-Atx-30Q, 53Q, and 82Q.
The ability to coimmunoprecipitate ATXN1 and RORa from cerebellar extracts in the absence of a direct interaction between the two proteins indicates that ATXN 1 interacts directly with a component of the RORa complex other than RORa itself. At the promoter of Purkinje cell-specific genes, RORa exists in a complex that includes many coregulators (Gold et al., 2003) . One protein found consistently in the RORa complex at Purkinje cell-specific genes is the coactivator Tip60 (Brady et al., 1999) . Based on this observation, we tested whether ATXN1 interacts with Tip60. Coimmunoprecipitations using cerebella extracts from wild-type mice indicated that endogenous ATXN1 and Tip60 do interact ( Figure 5C ). The ability of GST-ATXN1 to pull down Tip60 from wild-type mouse cerebella extracts provided additional evidence that ATXN1 and Tip60 interact ( Figure 5D ). Furthermore, the GST-ATXN1 pull down results suggested that as the length of the polyglutamine tract increased from 30Q to 53Q to 82Q the amount of Tip60 pulled down increased. The effect of the ATXN1 polyglutamine tract length on its interaction with Tip60 was also assessed using coimmunoprecipitations from transfected tissue culture cell extracts. Figure 5E shows that more ATXN1[82Q] was coimmunoprecipitated with Tip60 than was ATXN1[30Q], providing further evidence for a polyglutamine effect on the interaction of ATXN1 with Tip60.
To assess if ATXN1 and Tip60 might interact directly, we utilized GST-ATXN1 pull-downs of in vitro transcribed/ translated Tip60. In contrast to the results obtained when this approach was used to assess the interaction of ATXN1 with RORa, Figure 5F shows that GST-ATXN1 was able to pull down in vitro transcribed/translated Tip60. However, this analysis failed to provide evidence of a polyglutamine tract effect. When the amount of GST-ATXN1 was taken into account, GST-ATXN1-30Q, -53Q, and -82Q appeared to interact withTip60 equally.
In light of the evidence that ATXN1 interacts directly with Tip60, the regions of ATXN1 responsible for this interaction were mapped. We generated a series of constructs encoding FLAG-tagged fragments that spanned the Figure 2D ) is reduced at both 20 (p = 0.01) and 24 (p = 0.013) weeks of age in B05/B05:staggerer (sg) heterozygous mice compared to B05/+:Rora wild-type mice. Statistical significance was determined using a student's t test. length of wild-type ATXN1 ( Figure 6A ). These constructs were cotransfected with Tip60 into COS cells. As shown in Figure 6B , the results reveal that amino acids 425-547 of ATXN1 have a critical role in ATXN1's interaction with Tip60. The two fragments of ATXN1 containing amino acids 425-547, fragment III and IV, interacted with Tip60 at least as well as intact ATXN1[30Q] did. In contrast, fragments lacking this portion of ATXN1 interacted to a lesser extent with Tip60 than did full-length ATXN1[30Q]. Notably, these include the N-terminal 360 amino-acid fragment containing the polyglutamine stretch and the C-terminal fragment spanning amino acids 568-816 containing the AXH domain (Chen et al., 2004) .
Although the N-terminal 360 amino-acid fragment containing a wild-type polyglutamine stretch (30 residues) did not interact strongly with Tip60, the same fragment containing a mutant polyglutamine stretch (82 residues) did interact with Tip60 ( Figure 6C ). This may be because two regions of full-length and properly folded ATXN1 are involved in the interaction with Tip60. It is also possible that the self-association or aggregation properties of the exposed polyglutamine stretch leads to a detectable interaction with Tip60 through a nonspecific effect. Regardless, deciphering relevance of the polyglutamine-length effect on the interaction between Tip60 and the N-terminal fragment of ATXN1 is complicated by the absence of a polyglutamine-length effect in GST pull downs from in vitro translated Tip60 experiments.
DISCUSSION
We demonstrate that delaying expression of mutant ATXN1 until completion of cerebellar maturation dramatically reduced the susceptibility of adult Purkinje cells to mutant ATXN1-induced neurodegeneration. We propose that the molecular mechanism employed by mutant ATXN1 to influence cerebellar development and induce neurodegeneration in adult Purkinje cells is its ability to induce the loss of RORa from Purkinje cell nuclei. This leads to a reduced expression of RORa-mediated genes that are critical for Purkinje cell development and function.
Expression of Rora begins embryonically around day E14.5 (Nakagawa et al., 1997) , while endogenous Sca1 is first detectable at the beginning of postnatal week 2 (Banfi et al., 1996) . Expression of these two genes overlaps during a substantial portion of postnatal cerebellar development in the mouse. Throughout the first 3 postnatal weeks, the cerebellum increases in size by 1000-fold and undergoes a series of dramatic developmental changes to establish its adult structure and function (Goldowitz and Hamre, 1998) . During this period, the external granule layer seeds the internal granule layer with granule cells, and Purkinje cells mature, elaborating their dendritic trees and forming synapses with granule cells. This is also the time when the major inputs into the cerebellar cortex arise: climbing fiber inputs to Purkinje cells from the inferior olive and the mossy fiber inputs to the granule cells.
Insight into the molecular components of Purkinje cell development targeted by mutant ATXN1 came from a microarray analysis of gene expression in the SCA1 mice. Previous results from subtractive cDNA cloning and microarray-based gene expression profiling studies indicated that genes whose products have a role in calcium and/or glutamate signaling were downregulated prior to the onset of symptoms in SCA1[82Q] mice (Lin et al., 2000; Serra et al., 2004) . Efforts to understand the physiological basis of these results were complicated by the fact that in many instances the genes identified had opposing effects on signaling. The critical step in linking many of the genes downregulated in SCA1[82Q] mice came upon comparing the SCA1 microarray data with similar data obtained using the staggerer mouse (Gold et al., 2003) . Staggerer (sg/sg) mice have a deletion of Rora, encoding the retinoid-related orphan nuclear-receptor transcription factor RORa (Hamilton et al., 1996) . RORa is highly expressed by Purkinje cells (Ino, 2004) , and its loss blocks Purkinje cell maturation (Landis and Sidman, 1978; Hatten and Messer, 1978) , resulting in a congenital ataxia and hypoplastic cerebellum.
Many of the RORa-mediated genes whose expression was decreased in SCA1 [82] cerebella are highly expressed by Purkinje cells ( Figure S3 ). What's more, loss-of-function mutations for several of these genes result in an ataxic phenotype. For example, mice with targeted mutations in Calb1 (Airaksinen et al., 1997) , Itpr1 (Matsumoto et al., 1996) , Rora (Hamilton et al., 1996; Dussalt et al., 1998; Steinmayr et al., 1998) , Slc1a6 (Huang et al., 2004) , and Grm1 (Aiba et al., 1994; Ichise et al., 2000) develop ataxia. In addition, dominant-negative mutations in the human homolog of Spnb3 cause spinocerebellar ataxia type 5 (Ikeda et al., 2006) . These results provide strong support that the SCA1/staggerer overlapping set of genes encode proteins important for Purkinje cell function, consistent with a reduction in their expression having a role in SCA1.
Our data showed that a disease-causing form of ATXN1-consistently induced the depletion of RORa from Purkinje cells. A subtle decrease in RORa was seen, by immunofluorescence, in mice overexpressing wild-type SCA1 [30Q] . This is of interest given that SCA1[30Q] overexpressing mice do have a very mild altered phenotype (FernandezFunez et al., 2000) . Importantly, no decrease in RORa was detectable in mice overexpressing a form of mutant ATXN1 that fails to cause disease due to the presence of a nonfunctional nuclear localization signal (NLS), or in Sca1À/À mice that lack expression of endogenous ATXN1. This last observation is key in that it demonstrates that the effect on RORa levels is a dominant property of ATXN1 [82Q] . Finally, the conditional mouse model of SCA1, where RORa levels were restored within just a few days of turning off the expression of mutant ATXN1, provides additional insight into the possible connection between RORa and SCA1. First, recovery of RORa preceded the recovery of the morphological and neurological symptoms in these mice (Zu et al., 2004) , suggesting that perhaps morphological and neurological recovery is linked to restoration of RORa. Second, we found that recovery of RORa protein occurred in the absence of a recovery of Rora mRNA. This provides evidence that the effect of mutant ATXN1 on RORa expression is at least in part due to an effect on RORa protein stability.
Although the means by which expansion of the polyglutamine tract in ATXN1 alters RORa stability in vivo is unclear, results of protein-protein interaction studies indicate that the relationship between RORa and ATXN1 extends to the molecular level. RORa and ATXN1 could be coimmunoprecipitated from cerebellar extracts prepared from wild-type mice, yet GST-ATXN1 was unable to pull down in vitro transcribed/translated RORa. Though either GST-ATXN1 or in vitro transcribed/translated RORa could lack a posttranslational modification critical for the two to interact directly, a more likely conclusion is that RORa and ATXN1 do not interact directly. Rather, their ability to be coimmunoprecipitated from cerebellar extracts reflects that they both can be part of the same complex. There is evidence that RORa (Gold et al., 2003) and nuclear receptors in general function as part of a number of coregulatory complexes that include coactivators and correpressors (Perissi and Rosenfeld, 2005) . The Tat-interacting protein, Tip60, is one nuclear-receptor coactivator (Brady et al., 1999 ) that has been placed in the RORa complex at the promoters of Purkinje cell-specific genes (Gold et al., 2003) . Our data showing an interaction between ATXN1 and RORa and a direct interaction between ATXN1 and Tip60 point to the existence of a complex containing ATXN1, RORa, and Tip60. This is consistent with and adds to the concept that RORa and Tip60 are within the same complex.
A complex containing ATXN1, RORa, and Tip60, in which there is a direct interaction between ATXN1 and Tip60, provides a situation whereby mutant ATXN1 might induce the destabilization of RORa. In transfected COS-1 cells, RORa is a short-lived protein (Moraitis and Giguè re, 2003) . Perhaps RORa is stabilized when it is located in a complex with Tip60. In this case, one could envision that this complex is disrupted and RORa destabilized by virtue of a direct interaction between mutant ATXN1 and Tip60. It is of interest, therefore, that our data on the interaction of ATXN1 and Tip60 showed some indication of a polyglutamine effect ( Figures 6D and 6E) .
Amino acids 425-547 of ATXN1 were shown to mediate its interaction with Tip60. Previously, this region of ATXN1 was designated as the self-association region based on its ability to promote the self association of ATXN1 in a yeast two-hybrid system . Interestingly, mice overexpressing in their Purkinje cells a version of ATXN1[82Q] lacking residues 425-547 developed a disease in which progression was slowed dramatically (Skinner et al., 2002) . This is in agreement with interactions mediated by this region of ATXN1, perhaps with Tip60/RORa, contributing to disease in vivo.
Thus far, several proteins that interact with ATXN1 have been identified as possible mediators of SCA1 pathogenesis. These include PQBP, SMRT, BOAT, and Gfi-1 (Okazawa et al., 2002; Tsai et al., 2004; Tsuda et al., 2005) . The portion of ATXN1 implicated in its interaction with Tip60 does not include the polyglutamine tract that mediates the interaction between ATXN1 and PQBP, nor does the Tip60 interacting region include the AXH domain of ATXN1, an OB-folding domain shared by ATXN1 and the transcriptional repressor HBP-1 (de Chiara et al., 2003; Chen et al., 2004) . The AXH domain does mediate the interaction of ATXN1 with RNA (Yue et al., 2001 ) as well as with SMRT (Tsai et al., 2004; Mizutani et al., 2005) and Gfi-1 (Tsuda et al., 2005) . Gfi-1 and Tip60/ RORa are unique in that they fulfill several criteria consistent with having a role in SCA1 pathogenesis. Thus, it is likely that ATXN1 participates in more than one pathway in Purkinje cells, with each pathway making some contribution to SCA1 pathogenesis.
Taking our in vivo and in vitro observations together with those of other studies, we propose that a critical determinant of SCA1 is the developmental timing of mutant ATXN1 expression. Moreover, this developmental contribution to SCA1 pathogenesis likely is the result of a disruption of RORa-mediated gene expression by mutant ATXN1. Thus the developmental processes impacted by mutant ATXN1 would be those mediated by RORa and take place when Sca1 and RORa are both expressed by Purkinje cells. One attractive candidate is the development of the stereotypical dendritic tree of the Purkinje cell. Timing of Purkinje cell dendritic development overlaps with the period of RORa/ATXN1 coexpression (Armengol and Sotelo, 1991) . Recently, Boukhtouche et al. (2006) reported that RORa plays a crucial role in the development of the Purkinje cell dendritic tree. They suggested that RORa has a role in the remodeling that occurs early in the development of the Purkinje cell dendritic tree. This disruption likely extends into the adult since heterozygous staggerer mice have an age-dependent atrophy of their Purkinje cell dendrites (Hadj-Sahraoui et al., 2001) . Despite the apparent developmental component to the course of SCA1 in Purkinje cells, no obvious structural abnormalities of dendrite development have been noted in the SCA1 mice (Clark et al., 1997) . This suggests that the SCA1-associated disruption in Purkinje cell development is likely to be subtle.
In summary, we conclude that a decrease of RORa-mediated gene expression during development is an important factor in the susceptibility of Purkinje cells to SCA1. What might be the relevance of these observations to SCA1 in humans and perhaps neurodegenerative disease more generally? We suggest this work demonstrates that a failure of neurons to develop fully, even in the absence of having an immediate effect on phenotype, can result in a decreased ability of adult neurons to handle an insult.
EXPERIMENTAL PROCEDURES
DNA Microarray Analysis
Microarray data was obtained as described (Serra et al., 2004 ) and analyses performed using Gene Data Expressionist Version 5, Refiner 5.0.6, Analyst 5.0.6. Criteria used to detect differences in gene expression were p values % 0.05 and a fold change R 1.5. Immunoprecipitation and Western Blot Analysis of Cerebellar Extracts Cerebellar homogenates were prepared from each genotype, and immunoprecipitations were performed using either the anti-ATXN 1 antibody 11750 , anti-RORa sc-6062 (Santa Cruz, CA), or anti-Tip60 sc-25378 (Santa Cruz, CA). Subsequent western blot analysis was performed with the anti-ATXN 1 antibody 11750, with anti-RORa (SC-26380 at 1:500; Santa Cruz, CA), or with antiTip60 (SC-25378 at 1:1000; Santa Cruz, CA) (see Supplemental Data).
Immunofluorescence
Immunofluorescent staining of mouse cerebellum was performed as previously described (Skinner et al., 1997) . Briefly, epitopes were unmasked using 0.01 M urea. The sections were blocked for 1 hr in 2% normal donkey serum and incubated for 48 hr with the primary antibodies either anti-ATXN 1 antibody 11750 or 11NQ, anti-RORf (SC-6062) or anti-calbindin (SC-9848). The sections were washed in phosphate-buffered saline (PBS) and incubated for 48 hr with secondary antibody conjugated to Alexa Fluor 488 or Cy 3. Confocal images were collected (Bio-Rad, MRC 1000) with the collection parameters held constant. For further detail, see Supplemental Data.
Quantification of RORa in Purkinje cells was measured using Image Pro Plus analysis software (Media Cybernetics' Corporation, USA). Twelve bit confocal images were collected (Bio-Rad, MRC 1000) from three different animals in each genotype, and the average density of the mean was determined for approximately 50 Purkinje cells and interneurons from each animal. The average density of the mean of RORa in Purkinje cells was divided by the average density of the mean in interneurons, and the ratios were compared to FVB/n. Levels of RORa in interneurons were used as a control.
In Vitro Transcription/Translation GST Pull-Down Assay Full-length and partial human ATXN1 cDNAs were cloned into pGEX family vectors (Amersham Biosciences) and expressed in E. coli BL21(DE3) cells. Fusion proteins in the supernatants were separated from bacterial proteins on a glutathione agarose column (Molecular Probes). Fusion-protein degradation products were removed by gelfiltration chromatography on a 300X 9 mm Superdex 200 column (Amersham Biosciences). For a pull-down experiment, 8-20 mg of fusion protein was pre bound to 20 ml packed glutathione agarose with 1 ml binding buffer (120 mM NaCl, 20 mM Tris-Cl pH 8.0, 1 mM DTT, 0.05% NP-40) for 30 min at room temperature. After binding, the supernatant was removed and replaced with 20 ml binding buffer and 11 ml of an in vitro transcription/translation reaction prepared according to the directions of the TnT Coupled Reticulocyte Lysate System (Promega) using [35S] methionine (Perkin Elmer) and pCDNA3.1 expression constructs for either mouse RORa or XPRESS-and Histagged human Tip60. Binding was allowed to proceed at room temperature for 20 min with occasional flicking to agitate the beads. Beads were washed 4 times in binding buffer, and protein was eluted with 30 ml 2X sample buffer (125 mM Tris pH 6.8, 2% sodium dodecylsulfate, 20% glycerol, 160 mM DTT, and 2 mM EDTA with 0.01% bromphenol blue).
GST Pull-Down from Cerebella Extracts SCA1 [30Q, 53Q, and 82Q] cDNAs were cloned into pGEX-2T (Amersham) to generate GST-ATXN1 fusion proteins and expressed in E. coli DH5. The fusion proteins were isolated from cell pellets by adding 200 ml of Cell Lysis Reagent (MagneGSTÔ Pull-Down System, Promega), 2 ml of RQ1 Rnase-Free Dnase and 1X protease inhibitor (Roche) with incubation at room temperature for 20-30 min on a rotating platform. The amount of bacterial extract used in each experiment was determined based on a Simply Blue SafeStain (Invitrogen) stained 4%-12% Nupage Bis-Tris polyacrylamide gel to assess levels of fusion-protein expression. The bacterial extracts were bound to 20 ml of MagneGSTÔ Particles (Promega) in MagneGSTÔ Binding/wash Buffer and incubated for 30 min at room temperature on a rotating platform. Beads were washed 3 times in MagneGSTÔ Binding/wash Buffer. After the last wash, the particles were resuspended in 20 ml of MagneGSTÔ Binding/wash Buffer. To each 5 ml aliquot of particles carrying GST-fusion protein (or GST control), 50 mg of cerebellar extract, 20 ml 10%BSA, and MagneGSTÔ Binding/wash Buffer were added to a final volume of 200 ml and incubated for 2 hr at 4 C with mild rotation. Immune complexes were washed 5 times with 400 ml of MagneGSTÔ Binding/wash Buffer. Beads were resuspended in 1X SDS sample buffer for 5 min at room temperature, removed and the supernatant was boiled for 5 min, run on a 4%-12% Nupage Bis-Tris polyacrylamide gel (Invitrogen), and transferred to nitrocellulose membrane (Protran, Schleicher and Schuell). The membrane was probed with anti-Tip60 antibody at 1:1000 (SC-25378; Santa Cruz, CA).
Deletion Constructs and Coimmunoprecipitation SCA1 deletion constructs were cloned into CSII-CDF-EF-3xFLAG-MCS (gift from Nik Somia). This vector contains three tandem flag epitope sequences at the amino terminus. Full-length SCA1 cDNA was digested with Sal I, treated with Klenow to fill in and digested with EcoR I, and then cloned into the EcoR I/Hpa I sites of CSII-CDF-EF-33 FLAG-MCS. Creation of the SCA1 fragments is described in Supplemental Data. COS-1 cells were cotransfected with the SCA1 constructs and pcDNA 3.1 HisA-Tip60 using lipofectamine plus reagent (Invitrogen) and harvested 48 hr posttransfection. Cell lysates were collected, and coimmunoprecipitations were performed using the FLAG-IP kit (catalog # FLAGIPT1-1KT, Sigma) as per instructions. Immunoprecipitated samples were run on 4%-12% Nupage Bis-Tris polyacrylamide gels, transferred to nitrocellulose membrane, and probed with antiTip60 antibody at 1:1000 (#07-038 Upstate). Total lysate controls were probed with anti-Flag-HRP antibody at 1:20,000 (#A8592 Sigma) or anti-Tip60 antibody.
Statistical Analysis
Data were expressed as the mean ± SEM. Data were analyzed using either a student's t test for the comparison of two groups or a oneway anova for the comparison of more than two groups. A Tukey's Honestly Significant Difference (HSD) Post Hoc Test was performed when necessary. 
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